Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis

İlter, Erdin; Karalök, Hakan; Tüfekçi, Ertuğrul Can; Batur, Osman

doi:10.1080/13697130600652180

Cited by 11 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risedronate 5 mg administration daily has the similar outcome compared to 35 mg given weekly, and once-weekly risedronate would be more popular among patients. [ 25 , 26 ] Due to the limited of the included RCTs, we did not perform a subgroup analysis, more RCTs were required.…”

Section: Discussionmentioning

confidence: 99%

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

Ren

Wang

2018

Medicine

View full text Add to dashboard Cite

Background:Recent study has reported that risedronate was effective in reducing periprosthesis bone loss after total hip arthroplasty (THA). The meta-analysis was performed to compare the clinical outcomes of THA with oral risedronate versus placebo.Methods:Electronic databases: PubMed (1950–March 2018), EMBASE (1974–March 2018), the Cochrane Central Register of Controlled Trials, Web of Science (1950–March 2018) were systematically searched. Two authors independently graded the methodological quality of each eligible study using the Cochrane Collaboration tool and extracted relevant data. Statistical heterogeneity among the trials were evaluated with chi-square and I-square tests. This meta-analysis was performed using STATA 14.0.Results:A total of 4 randomized controlled trials (RCTs) published between 2006 and 2015 were included in our study. The meta-analysis demonstrated that risedronate was associated with a significantly reduction of periprosthetic bone mineral density after THA. No increased postoperative complications were observed.Conclusion:Oral risedronate might reduce the periprosthetic bone resorption after cementless THA. Additionally, no severe adverse effects were observed. High-quality RCTs with large sample size were still required.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

Ren

Wang

2018

Medicine

View full text Add to dashboard Cite

show abstract

“…Upon further assessment of the remaining 2178 articles, we excluded 415 studies of non‐RCTs, 837 as unrelated to PO, 898 as irrelevant unrelated drugs for the treatment of PO, 1 study without data resources or incomplete documentation. Eventually, 27 RCTs were found eligible for this network meta‐analysis from 1998 to 2016 (Supplementary Figure 1). A total of 18 RCTs were conducted in Caucasians, and 9 RCT was conducted in Asians.…”

Section: Resultsmentioning

confidence: 99%

A network meta‐analysis on the short‐term efficacy and adverse events of different anti‐osteoporosis drugs for the treatment of postmenopausal osteoporosis

Liu

Wang

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

A network meta-analysis was conducted to compare the short-term efficacy and adverse events of different drugs for the treatment of postmenopausal osteoporosis (PMO), providing a more effective treatment for PMO. We initially searched through various databases like PubMed, Cochrane Library, and EMBASE from inception till October 2016. All randomized controlled trials (RCTs) of drugs for the treatment of PMO were included for direct and indirect comparison. A combination of direct and indirect evidence of different inhibitors of anti-diabetic drugs for treatment of PMO were considered for calculating the weighted mean difference (WMD) value or odd ratio (OR) value and to draw surface under the cumulative ranking (SUCRA) curves. Twenty-seven RCTs were ultimately incorporated into this network meta-analysis comprising of 48 200 patients suffering from PMO. The network meta-analysis revealed that compared with placebo, alendronate had better efficacy on improving bone mineral density (BMD) at lumbar spine, femoral neck, and total hip. Risedronate and raloxifene had relatively lower incidence of new vertebral fractures. The SUCRA analysis showed that alendronate had better efficacy on improving BMD, risedronate could significantly decrease the incidence of fresh fracture and bazedoxifene was relatively safe. The available evidence suggested that alendronate and risedronate might be the superior choices for the treatment of PMO, while bazedoxifene was a comparatively safer option for patients.

show abstract

“…Biomarkers such as N-telopeptide (NTX), deoxypyridinoline (DPD), and tartrate-resistant acid phosphatase (TRAP) are employed to gauge the rate of bone resorption, making them valuable in the diagnosis, treatment, and monitoring of pathological fractures associated with osteoporosis. [ 9 , 11 ] NTX, a fragment of N-telopeptides produced during bone resorption, is quantified in urine and offers insight into the pace of bone resorption. NTX measurements contribute to osteoporosis diagnosis, as increasing levels correlate with declining bone mass.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, CTX levels can be influenced by various factors, including corticosteroid use and kidney impairment, which can lead to elevated CTX levels. [9][10][11] CTX can also be juxtaposed with other markers for comprehensive monitoring of bone health. Additional peptide markers of bone resorption include N-telopeptide (NTX), deoxypyridinoline (DPD), and tartrate-resistant acid phosphatase (TRAP), all of which are integral to gauging bone resorption rates.…”

Section: Discussionmentioning

confidence: 99%

The role of bone turnover markers in diagnosis, monitoring, and pathological fractures of osteoporosis

Altınsoy

2024

Ulus Travma Acil Cerrahi Derg

View full text Add to dashboard Cite

BACKGROUND: We investigated the utility of specific biomarkers—namely, c-terminal telopeptide (CTX), n-telopeptide (NTX), deoxypyridinoline (DPD), and tartrate-resistant acid phosphatase (TRAP)—compared to conventional diagnostic methods. We hypothesized that these novel biomarkers could hold substantial value in the diagnosis, treatment, and monitoring of osteoporosis. METHODS: The study was conducted over a three-year period, from January 1, 2020, to January 1, 2023. We enrolled a total of 520 patients aged 50 years or older who had been diagnosed with osteoporosis. Patients undergoing steroid treatments, which are known to contribute to osteoporosis, were excluded from the study. Additionally, we carefully selected and matched a control group consisting of 500 patients based on demographic characteristics relevant to the diagnosis of osteoporosis. This meticulous selection process resulted in a comprehensive cohort comprising 1,020 patients. Throughout the study, patients were closely monitored for a duration of one year to track the occurrence of pathological fractures and assess their overall prognosis. RESULTS: As a result of our rigorous investigation, we identified CTX, NTX, DPD, and TRAP as pivotal biomarkers that play a crucial role in evaluating bone health, monitoring treatment effectiveness, and detecting pathological fractures in the context of osteoporosis. CONCLUSION: Our study underscores the significance of these biomarkers in advancing the diagnosis and management of osteoporosis, offering valuable insights into the disease’s progression and treatment outcomes.

show abstract

Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis

Cited by 11 publications

References 9 publications

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

A network meta‐analysis on the short‐term efficacy and adverse events of different anti‐osteoporosis drugs for the treatment of postmenopausal osteoporosis

The role of bone turnover markers in diagnosis, monitoring, and pathological fractures of osteoporosis

Contact Info

Product

Resources

About